FindTrial
Sign In

Effects of the Chunghyuldan on the Prevention of Hemorrhagic Stroke Recurrence

Efficacy and Safety of Chunghyuldan in the Prevention of Hemorrhagic Stroke Recurrence: A Retrospective Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0010471
Enrollment
1000
Registered
2025-05-19
Start date
2025-04-14
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Kyung Hee University Oriental Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients 19 years of age or older who have been diagnosed with intracranial hemorrhage (I61) or subarachnoid hemorrhage (I60) based on a combination of brain imaging (Brain CT or MR) and clinical symptoms. - Patients who have been prescribed and have been taking chunghyuldan (DHH333) for 30 days or more to prevent hemorrhagic stroke recurrence. - Patients who have been followed for at least 2 years after starting to take the chunghyuldan

Exclusion criteria

Exclusion criteria: - Patients who have been followed for more than 2 years but have insufficient medical records to determine whether they have had a recurrent hemorrhagic stroke. - Other patients deemed inappropriate for study analysis by the principal investigator or research investigator.

Design outcomes

Primary

MeasureTime frame
Recurrence of hemorrhagic stroke—

Secondary

MeasureTime frame
Demographic information;comorbidities;social history;concomitant medications;type of hemorrhagic stroke;history and details of surgery related to hemorrhagic stroke;follow-up duration;adverse events—

Countries

Korea, Republic of

Contacts

Public ContactHan-Gyul Lee

KyungHee University Medical Center

kmdleehg@gmail.com+82-2-958-9128

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026